SCHEMBL7579074

SCHEMBL7579074

COC(=O)CCCN(C)C1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGFR P00533 17/20 0.61
ERBB2 P04626 11/20 0.61
HPGD P15428 1/20 0.61
HTT P42858 1/20 0.61
CSNK2A1 P68400 1/20 0.49
MAPT P10636 1/20 0.47
HDAC3 O15379 7/20 0.44
HDAC4 P56524 7/20 0.44
HDAC1 Q13547 7/20 0.44
HDAC7 Q8WUI4 7/20 0.44
HDAC2 Q92769 7/20 0.44
HDAC10 Q969S8 7/20 0.44
HDAC11 Q96DB2 7/20 0.44
HDAC8 Q9BY41 7/20 0.44
HDAC6 Q9UBN7 7/20 0.44
HDAC9 Q9UKV0 7/20 0.44
HDAC5 Q9UQL6 7/20 0.44
BRAF P15056 1/20 0.44
KDR P35968 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7579064 1.00 EGFR (0.61) EGFRERBB2HPGDHTTCSNK2A1
SCHEMBL7578924 0.96 EGFR (0.63) EGFRERBB2HPGDHTTCSNK2A1
SCHEMBL7578914 0.96 EGFR (0.63) EGFRERBB2HPGDHTTCSNK2A1
SCHEMBL7588551 0.93 EGFR (0.63) EGFRERBB2HPGDHTTCSNK2A1
SCHEMBL7588562 0.93 EGFR (0.63) EGFRERBB2HPGDHTTCSNK2A1
SCHEMBL7579135 0.92 EGFR (0.65) EGFRERBB2HPGDHTTCSNK2A1
SCHEMBL7579119 0.92 EGFR (0.65) EGFRERBB2HPGDHTTCSNK2A1
SCHEMBL7585267 0.90 EGFR (0.65) EGFRERBB2HPGDHTTCSNK2A1
SCHEMBL7585249 0.90 EGFR (0.65) EGFRERBB2HPGDHTTCSNK2A1
SCHEMBL7580715 0.88 EGFR (0.65) EGFRERBB2HPGDHTTCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020082420-A1 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082420-A1 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them PKD1, REN, CYP11B1 EGFR 1041/4885ERBB2 2419/4885HPGD 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.